December 18, 2024 — MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, today announced that the United States Food and Drug Administration (FDA) has granted Orphan-Drug Designation to YL201, for the treatment of small cell lung cancer (SCLC). YL201 is an investigational B7H3-targeted ADC, developed based on MediLink’s proprietary TMALIN® (Tumor Microenvironment Activable LINker) technology platform.
2024-12-18
December 1st, 2024 -- The investigator meeting of the phase III study in nasopharyngeal carcinoma for YL201, (a B7-H3 targeted antibody-drug conjugate), was held in Guangzhou, China. More than 70 experienced oncology experts from over 60 clinical sites (including many top oncologists from major academic cancer institutions across the country) attended the meeting to review and discuss the cutting-edge ADC technology in the treatment of nasopharyngeal carcinoma. The entire meeting was filled with an atmosphere of passion and a spirit of collaboration. YL201, a targeted antibody-drug conjugate is based on MediLink's TMALIN® platform and has received significant attention.
2024-12-02
On November 9, oncologists from more than 70 clinical research centers and experts from clinical trial institutions gathered in Guangzhou to participate in the multi-center, randomized controlled, open-label Phase III study of "Evaluating the efficacy and safety of YL201 for injection versus Topotecan hydrochloride for injection in patients with recurrent small cell lung cancer" organized by MediLink Therapeutics. Based on the availability of SCLC treatment in today's market and unmet clinical needs, in-depth exchanges and high-quality discussions were conducted regarding the design, preliminary clinical data, phase II study of YL201 and YL201-CN-302-01 research plan.
2024-11-09
2024-10-18Learn more
2024-10-08Learn more
2024-09-27Learn more
2024-09-14Learn more
2024-05-27Learn more
2024-05-02Learn more
